COSCIENS Biopharma Inc.

COSCIENS BIOPHARMA INC's next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, COSCIENS BIOPHARMA INC maintains a current ratio of 4.33, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.18, indicating elevated leverage, while an interest coverage ratio of -21.89 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, COSCIENS BIOPHARMA INC posted a return on equity (ROE) of 59.74, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 28.24, measuring how efficiently the asset base is converted into earnings. The company generates approximately 233,789.81 in revenue per employee across its workforce of 31.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.25 indicates how many times COSCIENS BIOPHARMA INC sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, COSCIENS BIOPHARMA INC recorded 8,753.00 in income tax expense. The company reported a pretax loss of -3.83M and 5.74M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on July 3, 2026, COSCIENS BIOPHARMA INC's stock has declined approximately 26.90% over the past 52 weeks. The 50-day moving average sits at 1.71, while the 200-day moving average is 1.73.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -3.30M, while operating income came in at -4.12M.

As of June 30, 2026, COSCIENS BIOPHARMA INC holds 4.62M in cash and equivalents against 1.71M in total debt, resulting in a net debt position of -4.62M. Total book value stands at 12.99M, with working capital of 6.52M providing operational flexibility.

COSCIENS BIOPHARMA INC produced -3.26M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, COSCIENS BIOPHARMA INC posted a gross margin of 45.41, reflecting its pricing power and cost economics. The operating margin of -56.80 and net profit margin of 79.14 provide insight into operational efficiency.